Bank of New York Mellon Corp Sells 29,481 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Bank of New York Mellon Corp cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,214,337 shares of the medical equipment provider’s stock after selling 29,481 shares during the quarter. Bank of New York Mellon Corp’s holdings in Zimmer Biomet were worth $109,800,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZBH. DV Equities LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $30,000. Gen Wealth Partners Inc acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet during the 4th quarter valued at approximately $32,000. Finally, Grove Bank & Trust boosted its stake in Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.28% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $89.69 on Tuesday. The business’s fifty day moving average price is $87.37 and its two-hundred day moving average price is $89.82. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The stock has a market capitalization of $17.35 billion, a price-to-earnings ratio of 23.30, a price-to-earnings-growth ratio of 2.68 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same period last year, the business earned $1.81 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Wall Street Analyst Weigh In

Several research analysts have commented on ZBH shares. Wells Fargo & Company dropped their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Finally, Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $100.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.